HHS awards BioCryst $12 million contract
This contract would allow BioCryst to further develop its candidate treatment for Ebola virus disease that has been shown to be effective in nonhuman primate models. In these tests, the drug BCX4430 prevented the reproduction capability of Ebola and Marburg viruses. This indicates that it could be a potential broad spectrum option for hemorrhagic fevers.
The contract could be extended to August 2017 and up to $35 million.
“Developing drugs and vaccines to protect against Ebola has been a long-term goal of the U.S. government,” ASPR's Biomedical Advanced Research and Development Authority (BARDA) Director Robin Robinson said. “We are making progress quickly to develop product candidates for clinical evaluation and to make products available that protect against this virus.”
The treatment is currently in the first phase of clinical trials with healthy volunteers with funding from the National Institutes of Health. During this time, BARDA support will enable the enhancement of production capabilities in order to scale up manufacturing.
BCX4430 is the first treatment of this kind to receive BARDA support.